Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial

Reuters

2025/10/24

<a href="https://laohu8.com/S/VSTM">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial

Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577533008"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577533008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577533008?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577533008","market":"us","top_or_hot":-1,"title":"Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL7tcJFP:1","article_id":"2577533008","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577533008","pubTimestamp":1761249688,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D  inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels  have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"Verastem报告KRAS G12D抑制剂在正在进行的1/2a期试验中取得令人鼓舞的早期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9},"content_text":"Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    \n\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}